Navigation Links
BioMS Medical Provides Update On Pipeline Products
Date:5/9/2008

entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to MBP8298 in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces conference call and web cast for Annual General Meeting
2. BioMS Medical to Participate in Speciality Panel Session at BioFinance 2008
3. BioMS Medical to present at EQUITIES Conference
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical to present at BioCentury Conference
6. BioMS Medical Announces 2007 Year End Results
7. BioMS Medical to present at BIO CEO & Investor Conference
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medical announces third quarter 2007 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Research and Markets  has announced the addition of ... Chromatograph Market by Type , Technology, Spectroscopy, Gas chromatography, ... to 2013 - 2020" report to their offering. ... analytical instrument that provides chemical composition data on process ... which companies carry out their production and improve the ...
(Date:9/29/2014)... ACEA Biosciences, Inc. (ACEA) has ... iCELLigence Research Grant for his proposal on cancer ... an impedance based real-time label-free cellular analysis instrument. ... Biomedical Engineering at Yale University currently holds a ... Professor Rong Fan's laboratory involve the ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... 2014  The 12th Cold Chain GDP & ... September 29 at the John B. Hynes Convention Center. ... for a weeklong conference attracting industry executives ... is designed to cover the industry,s most pressing topics, ... all temperature range products, GDP compliance requirements and supply ...
Breaking Biology Technology:Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 2Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 3Global Process Liquid Analyzer, Gas Analyzer, and Gas Chromatograph (PH/ORP, Chlorine, Oxygen, Carbon dioxide) Market - Trends & Forecast to 2020 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2SQI Diagnostics Announces New Chairman of Board of Directors 212th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2
... KYOTO, Japan and MARCY L,ETOILE, France , ... today that they have entered into a partnership to ... microbiology laboratories. bioMerieux will work with Shimadzu and their ... spectrometry technology for optimized integration into the microbiology laboratory ...
... , May 21 Micromet, Inc. (Nasdaq: MITI ... next-generation antibodies for the treatment of cancer, today announced that updates ... at two upcoming medical conferences. , ... Blinatumomab (MT103), the Company,s lead product candidate, will ...
... , BRISBANE, Calif. , May 21 InterMune, Inc. (Nasdaq: ... Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at ... May 26 at 3 p.m. EDT . , ... To access a live audio webcast of the presentation, investors ...
Cached Biology Technology:Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 2Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 3Shimadzu and bioMerieux Enter into Partnership for Mass Spectrometry Applications in Microbiology 4Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 2Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences 3InterMune to Present at 2010 Citi Health Care Conference 2
(Date:9/29/2014)... inhibitor dabrafenib has significant anti-tumour activity in patients ... cancer whose disease has progressed after chemotherapy, according ... 2014 Congress in Madrid, Spain. , "Reports ... generated considerable interest because these mutations may be ... agents," says lead author Dr David Planchard, pulmonary ...
(Date:9/29/2014)... in French . ... of days an expectant mother was deprived of electricity ... of her child, a new study finds., Scientists from ... have detected a distinctive ,signature, in the DNA of ... ice storm. Five months after the event, researchers recruited ...
(Date:9/29/2014)... a previously unknown mechanism by which estrogen prepares ... of estrogen-positive breast cancers, resist cancer drugs. The ... breast cancer therapy and will help doctors predict ... The University of Illinois team reports its findings ... pre-activates the unfolded-protein response (UPR), a pathway that ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... world over, are hungry for more meat, milk and ... has prompted explosive growth in livestock production and massive ... new textbook, Animal Manure Recycling: Treatment and Management, draws ... to put environmental problems to work and ensure the ...
... Department of Energy is making good on the second phase of ... study led by Dr. Joshua Yuan, Texas A&M AgriLife Research plant ... Yuan, who was granted $1.8 million for Phase I ... potential fuel source., The scientist said his research is moving ahead ...
... a new model for a genetic eye disease, and shows ... monkeys can yield valuable information about the human brain. ... of the Society for Neuroscience and the world,s largest source ... models have long been central in how we understand the ...
Cached Biology News:New textbook tackles the sustainable recycling of manure 2Plant fuel project moves to second phase under US Energy Department grant 2Understanding ourselves by studying the animal kingdom 2
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
Biology Products: